000306242 001__ 306242
000306242 005__ 20251118113425.0
000306242 0247_ $$2doi$$a10.3390/cancers13143630
000306242 0247_ $$2pmid$$apmid:34298855
000306242 0247_ $$2pmc$$apmc:PMC8307809
000306242 037__ $$aDKFZ-2025-02471
000306242 041__ $$aEnglish
000306242 082__ $$a610
000306242 1001_ $$aShalata, Walid$$b0
000306242 245__ $$aRapid Response to the Combination of Lenvatinib and Pembrolizumab in Patients with Advanced Carcinomas (Lung Adenocarcinoma and Malignant Pleural Mesothelioma).
000306242 260__ $$aBasel$$bMDPI$$c2021
000306242 3367_ $$2DRIVER$$aarticle
000306242 3367_ $$2DataCite$$aOutput Types/Journal article
000306242 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1763462039_1939186
000306242 3367_ $$2BibTeX$$aARTICLE
000306242 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000306242 3367_ $$00$$2EndNote$$aJournal Article
000306242 500__ $$a#DKFZ-MOST-Ca194#
000306242 520__ $$aThe new era of cancer treatments has made immune checkpoint inhibitors (ICIs) and emerging multikinase inhibitors (TKIs) the standards of care, thus drastically improving patient prognoses. Pembrolizumab is an anti-programmed cell death-1 antibody drug, and lenvatinib is a TKI with preferential antiangiogenic activity. We present, to our knowledge, the first reported series of cases consisting of patients with metastatic non-small cell lung cancer and malignant pleural mesothelioma who were treated with several types of chemotherapy combinations and ICIs followed by disease progression. They were subsequently treated with combined immunotherapy and TKI treatment, resulting in a near complete response within a very short time. Clinical responses were supported by in vitro testing of each patient's lymphocytic response to pembrolizumab after pre-exposure of target cancer cells to lenvatinib.
000306242 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000306242 650_7 $$2Other$$aNSCLC
000306242 650_7 $$2Other$$aimmune checkpoint inhibitor
000306242 650_7 $$2Other$$alenvatinib
000306242 650_7 $$2Other$$alung adenocarcinoma
000306242 650_7 $$2Other$$amalignant pleural mesothelioma
000306242 650_7 $$2Other$$amultikinase inhibitor
000306242 650_7 $$2Other$$apembrolizumab
000306242 7001_ $$00000-0001-5488-0996$$aIraqi, Muhammed$$b1
000306242 7001_ $$aBhattacharya, Baisali$$b2
000306242 7001_ $$00000-0001-5174-8535$$aFuchs, Vered$$b3
000306242 7001_ $$00000-0001-8455-9327$$aRoisman, Laila C$$b4
000306242 7001_ $$aCohen, Ahron Yehonatan$$b5
000306242 7001_ $$aMassalha, Ismaell$$b6
000306242 7001_ $$aYakobson, Alexander$$b7
000306242 7001_ $$aPrasad, Manu$$b8
000306242 7001_ $$00000-0003-3634-9098$$aElkabets, Moshe$$b9
000306242 7001_ $$aPorgador, Angel$$b10
000306242 7001_ $$aPeled, Nir$$b11
000306242 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers13143630$$gVol. 13, no. 14, p. 3630 -$$n14$$p3630$$tCancers$$v13$$x2072-6694$$y2021
000306242 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2022$$d2024-12-14
000306242 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-14
000306242 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-14
000306242 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-14
000306242 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-14
000306242 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-14
000306242 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-14
000306242 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-14
000306242 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-14
000306242 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-14
000306242 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-14
000306242 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2022$$d2024-12-14
000306242 980__ $$ajournal
000306242 980__ $$aI:(DE-He78)W500-20160331
000306242 980__ $$aI:(DE-He78)W510-20160331
000306242 9801_ $$aEXTERN4COORD